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PreventionBackground: Health economic evaluations are often required before implementing a vaccination pro-
gramme. Such evaluations rarely consider the historical context of a vaccination programme. We review
the financial history of vaccination programmes in the Netherlands, and compare these to demographic
and macroeconomic developments as well as avoided mortality burden.
Methods: Previously uncatalogued historical expenditures on the Dutch National Immunisation
Programme (NIP) and influenza vaccination were obtained from official reports. Costs were adjusted
for inflation using Consumer Price Indices and expressed in Euro of 2016. Estimates on mortality burden
averted were obtained from previous research and used to calculate the ratio of expenses to averted mor-
tality burden for vaccinations against diphtheria, tetanus, pertussis, polio, measles, mumps and rubella
for birth cohorts 1953–1992.
Results: Developments towards a uniform government funded NIP started early 1950s with vaccinations
against diphtheria, pertussis and tetanus, culminating in its official launch in 1957 together with polio
vaccinations. Since the 1980s, expenditure increased nearly five-fold mostly due to the addition of
new vaccines, while spending on already implemented vaccinations tended to decline. Overall, expendi-
ture increased from € 5 million in 1957 to € 93 million in 2014. Relative to total healthcare expenditure,
the NIP contributed little, ranging between 0.05% and 0.14%. Spending on influenza vaccination increased
from € 37 million in 1996 to € 52 million in 2014, while relative to total healthcare expenditure it
decreased from 0.069% to 0.055%. In 2014, 0.15% of healthcare expenditure and € 533 per birth was spent
on vaccination programmes. Overall, for birth cohorts 1953–1992, € 5.4 thousand (95% confidence inter-
val: 4.0–7.3) was expended per year-of-life-lost averted.
Conclusion: The actual costs per year-of-life gained are more favorable than estimated here since averted
medical costs were not included. Although expenditure on vaccination programmes increased substan-
tially, the contribution to overall healthcare expenditure remained small.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Currently, healtheconomicevaluationsof vaccinesarea common
partof vaccine research. In theNetherlands, the introductionsofnew
vaccinesaregenerallydiscussedbyaspecial committeeof theHealth
Council of the Netherlands on several criteria before they areconsidered for inclusion in the National Immunization Programme
(NIP). These criteria include the severity of the disease, effectiveness
and safety of the vaccine, its acceptability,whether the public health
issue is urgent enough, and the cost-effectiveness of the vaccine [1].
Cost-effectiveness analyses were not always part of the decision
making process surrounding vaccines. The merits of Edward Jen-
ner’s vaccine against smallpox were measured on its safety and
efficacy, not its costs. Similarly, the inclusion of diphtheria, pertus-
sis, tetanus, polio, measles, mumps, and rubella, were not
evaluated on their cost-effectiveness or cost-saving potential
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healthcare costs were by far not as prominent as they are nowa-
days. Also, the first vaccination programmes were introduced in
a time with higher infectious disease morbidity and mortality as
compared to today, which may have led to an easier decision on
implementation of preventive measures without a strong need
for economic arguments since the public health benefits were
more clear.
The economic aspects of vaccinations have only begun to play
an important role in decision making over the past several decades,
partially due to the substantial increase in healthcare expenditure
in most high income countries [3]. In addition, recently introduced
vaccines such as the pneumococcal vaccines and the vaccines
against human papillomavirus are much more complicated to pro-
duce, have a higher price, and their benefits are sometimes less vis-
ible than the older vaccines [4,5]. For a government with restricted
budgets, these developments have led policy makers to focus on
cost-effectiveness analyses of medical and preventive interven-
tions including vaccines [6].
The benefits, and indeed the cost-effectiveness, of many vacci-
nation programmes are well understood. However, these often
pertain to current and potential future vaccines, with less of a focus
on the history of vaccination programmes. For the Netherlands, the
historical mortality and morbidity benefits of vaccinations pro-
grammes have previously been explored, but historical expendi-
ture analyses have not been done [7,8]. Evaluations of costs, and
especially those for new and generally more expensive vaccines,
should be viewed in the context of vaccination programmes as a
whole and their history. Understanding their history may help to
better evaluate the benefits and costs of old and new vaccines
and furthermore will provide valuable insight into the develop-
ments of expenses over time for purposes of health care budgeting
and assessing the affordability of vaccination programmes.
To provide such an understanding, we review the historical
costs of vaccination programmes in the Netherlands up to 2014,
with a focus on childhood and influenza vaccinations. We discuss
the historical costs of the Dutch vaccination programmes and anal-
yse the developments in government expenditure on these pro-
grammes since implementation. In particular, we examine
whether the expenditure on vaccination programmes has
increased relative to other measures such as total healthcare
expenditure and Gross Domestic Product (GDP). Lastly, we utilize
results from previous studies on the impact of vaccination pro-
grammes on mortality burden averted in the Netherlands to give
a ballpark estimate of the combined costs and effects of vaccina-
tion programmes against diphtheria, tetanus, pertussis, polio,
measles, mumps, and rubella.2. Organisation and funding of vaccination programmes
2.1. Childhood vaccination programmes
Table 1 provides a brief overview of the developments around
vaccination programmes in the Netherlands. Officially, the Dutch
NIP was launched in 1957 with the start of mass vaccinations
against polio, but already in 1953 mass vaccinations against diph-
theria were implemented. Although a toxoid-vaccine against diph-
theria was available since the mid-1920s, diphtheria vaccinations
in the Netherlands were not widespread before 1953, with only
4–13% of the population being vaccinated in the early 1940s [9].
Vaccinations were generally provided by local private healthcare
providers or government bodies and administered by general prac-
titioners to children aged between 4 and 9 years, while most cases
of diphtheria occurred in younger children, thus limiting the
potential impact of these vaccinations. The vaccines were paidfor by parents, private or social health insurances, charities, or
other local funding organisations, but there was no coherence
between regions or a central coordination of vaccination efforts
[10].
In the early 1950s the Healthcare Inspectorate increased their
efforts to get more children vaccinated and at a lower age. To do
so, financial support was offered to Child Welfare Centers by pro-
viding a reimbursement of 1 Dutch Guilder for each registered vac-
cination starting in 1951 (1 Dutch Guilder in 1951 was equivalent
to a purchasing power of € 3.7 in 2016). This was done through a
local and government financed fund called the ‘Praeventiefonds’,
which was tasked to provide financial support to organisations
and groups to improve public health and combat disease. In
1953, the government extended its support by providing the vacci-
nes free of charge. Vaccines were produced or bought by the
National Institute for Public Health and provided through the
Healthcare Inspectorate. During this time, vaccines against pertus-
sis and tetanus became available and were provided for free
through the same structure. This marks the start of the develop-
ments that would eventually lead to the organized vaccination
programme we know today.
Providing financial support and consolidating the organisation
of vaccination efforts increased vaccination coverage (coverage of
the diphtheria vaccine for infants increased from 20% in 1953 to
over 50% in 1955 [7]), but it became clear that in order to reach
more children, closer collaboration between municipalities and
healthcare workers was required. To unite the organisations
involved in vaccinations, the first so-called ‘entgemeenschap’ was
launched in 1955. Within this collaborative framework, Child Wel-
fare Centers, local general practitioners, cross-organisations,
municipal health services, and local governments worked together
to coordinate vaccination efforts [11].
At the same time, it was recognized that a uniform registration
system of vaccination was needed to monitor the progress and suc-
cess of the vaccination campaigns. Since the 19th century a register
of smallpox vaccinations was already kept by municipalities and
was now extended with the new vaccines. At birth, children
received a card on which all vaccinations were to be registered.
With each vaccination, healthcare workers would send a note to
the local municipality where the vaccination was recorded.
All efforts of the preceding years came together with the mass
vaccination against poliomyelitis in 1957 which sparked an
increased public interest in vaccination. A major nationally coordi-
nated vaccination campaign, staged over multiple years, was
organised in which all children born since 1945 were invited to
be vaccinated against poliomyelitis. This catch-up vaccination pro-
gramme was executed from 1957 until 1962 and reached more
than 2.6 million children. It also marked the launch of the new reg-
istration system as well as the start of the expansion of the collab-
orative framework of ‘entgemeenschappen’ to the rest of the
Netherlands. The mass vaccination campaign against poliomyelitis
is therefore seen as the official start of the Dutch NIP [11]. Children
were generally vaccinated at Child Welfare Centers and at schools,
and since the official launch of the NIP practically all vaccinations
are administered through governmental channels without sub-
stantial private vaccination. Due to the new more uniform
approach, the coverage increased dramatically and by 1964 child-
hood vaccination coverage was over 90% [7]. Historically the cover-
age remained very high for all vaccines, with only the HPV vaccine,
introduced in 2010, lagging behind at an uptake of 45.5% for girls
born in 2003 [12].
The Praeventiefonds continued to financially support the NIP
until 1963,when theMinistryof SocialAffairs andPublicHealth took
over the complete funding of the vaccination programme, now con-
taining the vaccines against smallpox and the combined DTP-IPV-
vaccine (diphtheria-pertussis-tetanus-inactivated poliomyelitis).
Table 1
Short history of the Dutch National Immunization Programmes.
Year Vaccine Target group Modifications and other remarks Remarks on funding and organisation
1799 Smallpox School-going children and infants. Under 1 year of age.
1951 Start financial support of Child Welfare Centers
by the Praeventiefonds.
1953 Diphtheria Infants under 1 year of age. Government starts providing vaccines free of
charge.
1954 DTP Infants under 1 year of age. Diphtheria combined with
tetanus and pertussis in DTP.
1955 Start first ‘entgemeenschap’
1957 Poliomyelitis Catch-up campaign: everyone born since 1945 (3 doses).
Routine vaccination: 3-, 4-, 5-, and 11- month-olds (4
doses).
Official start of Dutch NIP.
DTP 3-, 4-, 5-, 11-month-olds (4 doses) Catch-up vaccinations were
offered at 4 and 9 years.
1959 ‘Entgemeenschappen’ extended over the rest of
the Netherlands.
1962 DTP-IPV 3-, 4-, 5-, 11-month-olds (4 doses). DTP combined with inactivated
poliomyelitis vaccine in DTP-IPV.
1963 Complete funding of the NIP provided by the
government.
1965 DT-IPV 4- and 9-year-olds.
1974 Rubella 11-year-old girls. Smallpox vaccination
discontinued.
Funding provided through social health
insurance.
1976 Measles 14-month-olds.
1987 MMR 14-month-old and 9-year-old boys and girls. Measles combined with mumps




3-, 4-, 5-. 11-month-olds (4 doses). As a separate vaccination. Government and other organisations funded a
national campaign to inform risk-groups of
influenza vaccination.
1995 Influenza Risk groups1 Start of nationally organised
influenza vaccination for risk-
groups.
1996 Influenza 65-year-olds and over. Influenza vaccination extended to
65-year-olds and over.
Influenza vaccination financed through social
health insurance.
1999 Starting age for DTP-IPV and Hib




4-year-olds. As a separate vaccine.
2002 Meningococcal
serotype C (MenC)
Catch-up campaign: everyone 18 years of age and
younger. Routine vaccination:14-month-olds
2003 Hepatitis B (HepB) 2-, 3-, 4-, and 11-month-old children with parents from
high risk countries and children from mothers who carry
hepatitis B-virus (4 doses).
DTP-IPV-Hib Hib combined with DTP-IPV in
DTP-IPV-Hib.
2005 Pertussis component in DTP-IPV-






2-, 3-, 4-, and 11-month-olds (4 doses). Coordination of influenza vaccination handed
to the National Institute for Public Health and
the Environment (RIVM).
HepB0 Directly after birth for children from mothers who carry
hepatitis B-virus.
HepB combined with DTP-IPV-Hib
for risk groups
DTaP-IPV Acellular pertussis for 4-year-olds
now combined in DTaP-IPV.
2007 ‘Entgemeenschappen’ integrated in RIVM.
2008 DTaP-IPV-Hib-
HepB
Children with down syndrome.
Influenza 60-year-olds and over. Target age for influenza




12-year-old girls (3 doses).
2011 PCV-10 PCV-10 replaces PCV-7.
DTaP-IPV-Hib-
HepB
2-, 3-, 4-, and 11-month olds. Now as a combination vaccine for
all children.
2013 PCV-10 2-, 4-, and 11-month olds. Change from four to three doses
of PCV-10.
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Table 1 (continued)
Year Vaccine Target group Modifications and other remarks Remarks on funding and organisation
2014 HPV Change from three to two doses of
HPV.
2018 MenACWY MenACWY replaces MenC. Dutch NIP incorporated in the Public Health
Act.
RIVM: National Institute for Public Health and the Environment. NIP: National Immunisation Programme.
Vaccines key: aP, acellular-pertussis; DTP, diphtheria-tetanus-pertussis; IPV, inactivated polio vaccine; Hib, Haemophilus influenza serotype b; HepB, hepatitis B; MenC,
meningococcal serotype C; MenACWY, meningococcal serotype A, C, W, and Y; MMR, measles-mumps-rubella; PCV, pneumococcal conjugate vaccine; HPV, human
papillomavirus.
1 Risk groups for influenza vaccinations were defined by the Health Council of the Netherlands.
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ernment funded social health insurance (the ‘AlgemeneWet Bijzon-
dere Ziektekosten’; AWBZ) which covers every Dutch citizen. All
subsequent vaccines that were added to the NIP were financed in
this way until 2015 when the AWBZ was abolished. In 2018, the
childhood vaccination programmeswere incorporated in the Public
Health Act, and in themean time it was covered directly by the bud-
get of the Ministry of Health, Welfare and Sports. Currently, the NIP
is coordinated by the National Institute for Public Health and the
Environment which is also responsible for communication on the
NIP, and the registration, purchase, storage, and distribution of
vaccines.2.2. Influenza vaccination programme
The first successful influenza vaccine was developed in the early
1940s and used by the US military in 1944 and 1945. In the follow-
ing two decades it became clear that the influenza virus mutates
rapidly and that the vaccine needs to be reformulated regularly
to match it with the expected strain of influenza, although an occa-
sional mismatch does occur [13].
Like the NIP, initially there was no national programme for
influenza vaccination in the Netherlands. Vaccinations were dis-
tributed by pharmacies and administered by and at general practi-
tioners and targeted towards risk groups. The Health Council of the
Netherlands reported each year on which risk groups should be
vaccinated. These groups included patients with respiratory or
heart problems, patients with diabetes mellitus, patients with
HIV, and other groups with medical conditions that impair an ade-
quate immune response. Individuals belonging to the risk groups
were invited each year by the general practitioner to receive the
influenza vaccine.
In 1991 the vaccination coverage among high risk groups in the
general population was estimated at around 28%, while coverage
among the risk groups may have been as high as 56% [14,15]. Vac-
cination was ongoing in earlier years and coverage was likely
around 5%, but little to no data are available [16]. Reasons for this
low vaccination coverage were that part of the target group refused
vaccination because of doubts about efficacy, fear of side-effects,
and because they thought it was not necessary. In addition, physi-
cians also had doubt about the efficacy of the vaccine, side effects,
the target groups to be vaccinated and how to reach them, and the
need to vaccinate. Finally, practical reasons about access and avail-
ability may have resulted in lower uptake, as patients were
requested to get the vaccine at the general practitioner [17].
In the early 1990s, the government and other organisations
decided to actively intervene and increase the coverage of influ-
enza vaccination. This was initially attempted by reaching out to
the risk groups through media campaigns. In 1992 and 1993 the
Ministry of Public Health, Welfare, and Sports, as well as other
organisations including pharmaceutical companies and the
National Organisation of General Practitioners, financed a national
campaign, including television commercials, to inform risk-groupson the annual influenza vaccination [18]. The next step was
achieved in 1995 when a national vaccination campaign was
organised by the National Organisation of General Practitioners.
This programme was extended in 1996 to also include everyone
over 65 years of age, a strategy which was shown to be favourable
in cost-effectiveness research [19]. Similar to the NIP, it was to be
financed by public funds through government funded social health
insurance. Although funded similarly, influenza vaccinations are
not part of the NIP but organised as a separate programme. Reason
for this separation is that the vaccination needs to be repeated each
year and target specific risk groups and the elderly rather than
focussing on children in general.
In 1997 the programme became officially known as the
National Programme Influenza Prevention and in 2008 the target
age was further extended to everyone over 60 years of age in addi-
tion to risk-groups. Currently, the programme is coordinated by
the National Institute for Public Health and the Environment
(RIVM) that also purchases and distributes the vaccines. In recent
years the vaccination coverage has been declining steadily from
71.5% in 2008 to 53.5% in 2016 [20,21]. This is possibly due to an
increase in healthy elderly within the target population who per-
ceive lower risks of influenza and are less willing to vaccinate.3. Price development of vaccines and vaccination programmes
3.1. Data and methods
We obtained previously uncatalogued historical expenditure
data on the NIP from 1951 up to 2014, from various official reports
ranging from annual reports of the Praeventiefonds, the Ministry of
Public Health, Welfare, and Sports and her predecessors, and other
official publications. For the periods 1973–1976 and 1978–1981 no
data was available. We also obtained the expenditure on influenza
vaccinations from 1996 up to 2014. These expenses reflect the gov-
ernment expenditure on the NIP and influenza vaccination, and
include vaccine costs, costs of administration, personnel costs,
and overhead costs, but may not contain all costs associated with
vaccination programmes, such as implementation costs or catch-
up campaigns. These costs are however minor compared to the
costs of vaccines and overhead costs themselves. For most periods
these costs were not separately specified. Expenditure on specific
vaccinations in the NIP from 1995 to 2013 (no data for 2014 were
available) were obtained from databases of the Dutch Health
Authority. For influenza vaccination, no specific expenditures were
available for the period 2004–2008 and cost for this period were
based on available subsidies as reported in the ‘Staatscourant’
(the official Dutch Government Gazette).
We obtained the number of births, population size, as well as
overall healthcare expenditure from Statistics Netherlands
[22,23]. For the overall healthcare expenditure, no data was avail-
able prior to 1972. Gross Domestic Product was obtained from the
Netherlands Bureau for Economic Policy Analysis [24]. We used
population and birth statistics to calculate the cost per capita
5702 M. van Wijhe et al. / Vaccine 37 (2019) 5698–5707(expenditure per year divided by the total population of that year)
and the cost per birth (expenditure per year divided by the total
number of live births of that year).
We adjusted the development of expenditures of the Dutch NIP,
GPD, and overall healthcare costs for inflation using the Consumer
Price Index (CPI) published by Statistics Netherlands [25]. By
adjusting for the general price development of a basket of con-
sumer goods and services, the movements in the expenditures on
the NIP are the combined result of changes in the volumes and
the specific price movements of vaccinations only. The expendi-
tures were expressed in prices of 2016 (in Euro) and data prior
to 2002 was first converted to Euro from Dutch guilders where €
1 = 2.20371 Dutch Guilder.
We expressed the expenditure on the NIP and influenza vacci-
nation programme relative to demographic changes (population
and births) and macroeconomic changes (total healthcare expendi-























































































































Fig. 1. Government expenditure on the Dutch National Immunisation Programme (NIP)
expenditure on the NIP, grey line indicates the expenditure on the influenza vaccination
costs are expressed in Euro of 2016 adjusted for inflation using Consumer Price Indexes. A
for the periods 1973–1976 and 1978–1981 were unavailable. Vaccines key: DTP-IPV, diph
old girls; MMR, measles-mumps-rubella, for both boys and girls of 14 months of ag
meningococcal C; HepB, hepatitis B; PCV-7, 7-valent pneumococcal conjugate vaccine; HPreviously we have analysed the childhood mortality benefits of
vaccinations programmes against diphtheria, tetanus, pertussis,
polio, measles, mumps, and rubella [7]. In short, we estimated
the years-of-life-lost among children and young adolescents (up
to 20 years-of-age; YLL20) born between 1953 and 1992, that are
prevented by vaccination programmes in the Netherlands. We
showed that the mortality burden for these diseases already
declined before the start of vaccination due to various other rea-
sons (like improvements in nutrition, welfare, housing conditions,
and so on), but that vaccines still contributed substantially in fur-
ther lowering mortality burden, for more details see [7]. Here, we
assess the ratio of the government expenditure on vaccination pro-
grammes for a certain year and the (previously) estimated YLL20
prevented for everyone born in that year. Because expenditure
was not reported separately during the period, it was not possible
to provide estimates separately for each vaccine. For years with























, 1951–2014 and influenza vaccination programme 1996–2014. Black line indicates
programme. Arrows indicate when new vaccines are included in the Dutch NIP. All
ll prices express government expenditure according to various official reports. Data
theria-tetanus-pertussis-inactivated poliomyelitis; rubella in 1974, only for 11-year
e; Hib, Haemophilus influenza serotype b; a-Pertussis, acellular-pertussis; MenC,
PV, human papillomavirus.
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bidity and only focusses on the mortality due to a select number of
diseases and only up to 20 years of age. Our purpose here is not a
formal cost-effectiveness analysis, which would go well beyond
the scope of this manuscript, but an indication of the costs per
year-of-life-lost prevented. As such, costs and YLL20 are also not
discounted.4. Results
Fig. 1 shows the total expenditure, expenditure per birth, and
expenditure per capita on the Dutch NIP and influenza vaccination
programme. In general, the expenditure on the NIP increased grad-
ually over time from € 5 million (mln) in 1957 to € 93 mln in 2014.
Government expenditure increased in particular since the end of
the 1980s. The increase in costs is mainly due to the addition of
new vaccines such as the MMR-vaccine in 1987, the vaccine
against Haemophilus influenza in 1993, acellular pertussis in 2001,
meningococcal C in 2002, and hepatitis B for risk groups in 2003.
The expenditure on the NIP increased again in 2006 with the inclu-
sion of PCV-7; from € 67 mln in 2005 to € 120 mln in 2007. The per
capita and per birth expenditure on the NIP followed a similar
trend, increasing from € 0.46 to € 5.54 per capita and € 21 to €
533 per birth between 1957 and 2014. At its peak in 2007 the
NIP cost € 7.37 per capita and € 665 per birth. Since 2007, the costs
of the vaccination programme have been declining. Similar to the
NIP, the expenditure on the influenza vaccination programme
increased, from € 37 mln in 1996 to € 52 mln in 2014. In total,
the government spent € 145 mln (€ 8.65 per capita) on the NIP
and influenza vaccination programme in 2014.
A breakdown of the costs of the NIP by vaccine is shown in
Fig. 2. While the total expenditure on vaccinations increased sub-














































Fig. 2. Breakdown of costs by vaccine from 1987 to 2013. All costs are expressed in Euro o
1991 to 1994, and for 2001 are missing. Vaccines key: aP, acellular-pertussis; DTP, diph
serotype b; HepB, hepatitis B; MenC, meningococcal C; MMR, measles-mumps-rube
differences in data sources, the timing of costs specified here may not correspond exactly
officially launched in 2010 for 12-year old girls but until 2012 the HPV programme wasspecific vaccine seemed to decline over time, possibly due to better
price tendering and international developments on the vaccine
market (when more competitors join the market). For example,
expenditure on the MMR-vaccine declined from € 6.9 mln in
1987 to € 2.6 mln in 2013. Reformulations of vaccines (such as
combining DTP-IPV-Hib with HepB) did not substantially impact
total expenditure. The main cause of the increase in costs in
2007 was the inclusion of the PCV-7 vaccine. In 2012, the expendi-
ture on PCV declined dramatically due to better pricing for the
PCV-10 vaccine.
Fig. 3 shows the expenditure on the NIP and influenza vaccina-
tions as proportions of the GDP and healthcare expenditure. Over-
all, expenditure relative to GDP and healthcare expenditure
increased as more mass vaccination programmes were imple-
mented in the Netherlands. The proportion of healthcare expendi-
ture spent on the NIP ranged between 0.05% and 0.14%. Similar to
the overal developments in vaccination expenditure, the propor-
tionate expenditure on the NIP increased up to 2007, after which
a steady decline was observed. Interestingly, relative healthcare
expenditure on influenza vaccination showed a decrease from
0.069% in 1996 to 0.055% in 2014. In total, 0.022% of GDP and
0.15% of healthcare expenditure was spent on vaccination pro-
grammes in 2014.
The ratio of expenditure to averted mortality burden among
children and young adults (expressed as costs per YLL20) born
between 1953 and 1992, for vaccinations against diphtheria, teta-
nus, pertussis, polio, measles, mumps, and rubella is presented in
Fig. 4. The costs per YLL20 averted changes over time for these vac-
cines. As the mortality burden averted declined the cost per YLL
averted increases from € 1.2 thousand (95% confidence interval:
€ 0.8 – € 1.9) in birth cohort 1953 to € 20.3 thousand (95% confi-
dence interval: € 15.1 – € 27.5) in birth cohort 1992. In total over
this period € 5.4 thousand (95% confidence interval: € 4.0 – €





















f 2016 adjusted for inflation using Consumer Price Indexes. Data prior to 1987, from
theria-tetanus-pertussis; IPV, inactivated poliomyelitis; Hib, Haemophilus influenza
lla; PCV, pneumococcal conjugate vaccine; HPV, human papillomavirus. Due to
to those in Fig. 1 or changes in the programme listed in Table 1. HPV vaccination was









































































































































Fig. 3. Government expenditure on vaccination programmes relative to macroeconomic developments. (A) Government expenditure relative to Gross Domestic Product
(GDP) 1951–2014 and (B) government expenditure relative to total healthcare expenditure 1972–2014. Top panels show the per capita GDP and total healthcare expenditure,
bottom panels show percentages expended on the National Immunisation Programme (NIP) and the influenza vaccination programme. All costs are expressed in prices of
2016 adjusted for inflation using Consumer Price Indexes. Data on cost of the NIP for the periods 1973–1976 and 1978–1981 are missing; no data is available on healthcare












































Fig. 4. Government expenditure on the Dutch National Immunisation Programme
per year of life lost up to age 20 years (YLL20) averted for birth cohorts 1953–1992.
Estimates on mortality burden averted among children and young adolescents up to
the age of 20 were obtained from [7]. The black line indicates expenditure on the
NIP per YLL20 averted by vaccination programmes and the grey area indicates the
95% confidence interval. All costs are expressed in Euro of 2016 adjusted for
inflation using Consumer Price Indexes. All prices express government expenditure
according to various official reports. Data for the periods 1973–1976 and 1978–
1981 were unavailable.
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Vaccines are often hailed as one of the most effective public
health methods in preventing infectious diseases. As the cost of
new vaccines increase and in time where policy makers are con-
fronted with limited resources and budget constraints, a historical
perspective and good understanding of the evolution of the expen-
diture on vaccination programmes may help give context to
today’s decision making problems and provide insight into the
affordability of these programmes. Here we explored the organiza-
tional and historical costs of vaccination programmes in the
Netherlands.
The expenditure on the Dutch National Immunisation Pro-
gramme has increased substantially over time, with a near five-
fold increase since the mid-1980s and a near doubling since the
early 2000s. We found that, both absolute and relative expenditure
spiked whenever a new vaccine was introduced, and that expendi-
tures tend to stabilise or decline when a vaccination programme
covered the same vaccines. In addition, while our approach is
not—and was not intended as—a full cost-effectiveness analysis,
our estimates indicate that vaccinations against diphtheria, teta-
nus, pertussis, polio, measles, mumps, and rubella have a very
favourable expenditure to averted mortality ratio.
There are two main reasons for the increase in vaccination
expenditure on the long term. First, the number of included vacci-
nes has increased. Nowadays, the Dutch NIP includes vaccines
against 12 infectious diseases. Second, new vaccines are
introduced at progressively higher prices. The current low costs
M. van Wijhe et al. / Vaccine 37 (2019) 5698–5707 5705of vaccines included in the early days of the Dutch NIP sharply con-
trast the new generation of vaccines which have much higher price
tags. These next-generation vaccines are more complex to manu-
facture and thus cost more in the early years of implementation.
Over time the costs of each specific vaccination, including the
more recent vaccinations, declined. The expenditure on the
MMR-vaccination for example declined by more than 60% between
1987 and 2014. This was partially due to tendering for better prices
and a decline in the number of births. That expenditure on specific
vaccinations declines over time is likely to be true for the newer
vaccines as well as evidenced by the decline in expenditure on
PCV after 2011. Vaccination against PCV-7 started in 2006 and dra-
matically increased the expenditure on the NIP. However, with the
shift to PCV-10 in 2011 and the change to a 3-dose schedule in
2013, prices dropped considerably.
Pneumococcal vaccination thus has had a sizable impact on the
overall expenditure on vaccination programmes in the Nether-
lands. While a formal cost-effectiveness analysis was beyond the
scope of this study, previous studies on the cost-effectiveness of
pneumococcal vaccines vary greatly, ranging from cost saving, to
borderline or unfavorable depending on the assumptions in the
models used [26–32]. For the Netherlands, cost-effectiveness stud-
ies show a similar picture with generally borderline to unfavour-
able cost-effectiveness ratios [28,33]. Mainly the steep price
coupled with serotype replacement resulted in relatively poor
cost-effectiveness ratios. These have improved however with the
change to a 3-dose PCV-10 schedule. Recent years has also seen
an increasing interest and implementation of vaccination of elderly
against pneumococcal disease [34,35]. In 2018, the Health Council
of the Netherlands advised in favour of vaccination with pneumo-
coccal polysaccharide vaccine (PPV-23) for the elderly in the
Netherlands [36].
Contrary to the childhood vaccination programmes, the expen-
diture on the national influenza vaccinations has not seen a drastic
increase since 1996. However, as the elderly population is
expected to increase in the coming decades due to the aging pop-
ulation, an increase in the expenditure on influenza vaccinations is
to be expected.
Although the total government expenditure on vaccination pro-
grammes has increased substantially, overall the impact on total
healthcare expenditure is very small. An earlier analysis showed
that spending on vaccinations in 2003 was € 8.96 per capita
(1.17% of total spending on prevention in the Netherlands); com-
pared to € 6.77 in our study [37]. Although the approaches differ
and included expenditure on screening, they broadly corroborate
our results. Compared to other European countries, the Nether-
lands spends relatively little of its healthcare budget on vaccina-
tion programmes, accounting for only 0.15% in 2014, and this has
been decreasing since 2007. In part this decline is due to the slow
implementation of new vaccines in the Netherlands. In an analysis
of seven other European countries spending on vaccine procure-
ment ranged from 0.25% (Spain, 2012) of healthcare budget to
0.47% (Germany, 2014) [38]. This may in part be due to differences
in the vaccines included and in financing of healthcare between
European countries and thus differences in total healthcare spend-
ing. An update to their analysis showed a similar picture for more
recent years [39]. In 2014, the Netherlands ranked 15th in the
world rankings of highest expenditure on healthcare as percentage
of GDP (9th on rankings per capita), spending 10.9% of its GDP on
healthcare; Germany ranked 10th with 11.3% while Spain ranked
40th [40].
The costs reported here may not include all costs that are
related to vaccination. It is often unclear what is actually included
in the reported government expenditure on vaccination pro-
grammes. For example the reported numbers may not include
expenses related to catch-up campaigns. For example, thecatch-up campaign with meningococcal serogroup C vaccine in
2002, is estimated to have cost at least € 76 mln [41]. Although
substantial, these are one-time expenses. In addition, while vacci-
nes are generally considered as safe, they might cause adverse
reactions, such as swellings at the injection site. These side-
effects may result in healthcare utilization and thus vaccine-
related healthcare costs. These costs were not taken into account
here. Nevertheless, the government expenditure on vaccination
programmes we reported here gives an indication of the order of
magnitude on how much these programmes have cost and how
the expenditures have developed over time.
Vaccination programmes are often considered amongst one of
the most cost-effective public health interventions and highly
effective in preventing infectious disease morbidity and mortality
[7,42–44]. Here we add to previous work by estimating the ratio
of expenditure to averted mortality burden for a selected number
of vaccinations [7]. Although the ratio increased over time, due
to declines in mortality burden, overall these ratios suggest that
vaccination programmes have been highly cost-effective. The
ratios presented here are similar but not identical to incremental
cost-effectiveness ratios. We only accounted for mortality burden
for a select number of diseases, and lacked the information
required for more specific calculation of morbidity for this period.
In addition, by preventing disease and mortality, vaccines also
avert medical cost incurred due to treatment of those diseases,
costs associated with productivity loss by parents tending to
stricken children, as well as other costs due to long-term sequelae.
These cost savings were not taken into account. As these costs
associated with disease can be substantially higher than the costs
of vaccination, many vaccines will be cost saving [45]. Some stud-
ies have suggested that the benefits of vaccination programmes
also extend to other areas such as lifetime income, increasing over-
all well-being, better school attendance of children due to
increased health, and as a consequence of these other benefits
gains in productivity and longevity [46,47]. Evidence for such
broader impacts remains limited [48].
For the near future, vaccination costs will increase further due
to the implementation of next-generation vaccines or extending
the target group of implemented vaccines. In 2018 meningococcal
vaccination against serotype C was replaced with the vaccine
against serotypes A, C, W, and Y. Moreover, the Health Council of
the Netherlands recommended vaccination against rotavirus for
infants with high-risk conditions (mainly preterm infants, infants
with a low birthweight, or infants with birth defects). Interestingly,
they also stated that vaccination of all children against rotavirus
would only be recommended when the cost-effectiveness would
be beneficial, i.e. the vaccine price would be low enough [49]. In
the near future, the Health Council of the Netherlands will advise
on a new vaccine against herpes zoster for the elderly. In addition,
new target-groups of existing vaccine are under consideration,
such as maternal pertussis vaccination (positive recommendation
by the Health Council of the Netherlands in 2015), pneumococcal
vaccination for elderly, HPV vaccination for boys, combined hepati-
tis A and B vaccination for children, and influenza vaccination for
children.
The success of a vaccination programmes is inherently tied to
the willingness of policy makers to finance the purchase and deliv-
ery of vaccines, the monitoring of their effects in terms of coverage,
adverse events, and the occurrence of the target diseases [4,50].
Because vaccination programmes are implemented on a large
scale, targeting entire birth cohorts, it is easy to perceive them as
costly endeavours. Using a historical perspective, we have shown
that vaccination programmes only constitute a small portion of
the government spending on healthcare and their total costs,
although increasing, are relatively low. We have also shown that
vaccination-programmes against diphtheria, tetanus, pertussis,
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den averted at relatively modest costs. Inclusion of a new vaccine
might result in an increase in expenditure. Such jumps in expendi-
ture should always be substantiated by additional health gains.
Moreover, the expenditure on these vaccines should always be
viewed in context with the history of vaccination programmes as
a whole; evaluations of the costs and effects of old and new vacci-
nes should not be done in isolation. Understanding the evolution of
vaccination programmes both in an organization and financial per-
spective may help put context to the budgetary impact of future
vaccines.6. Conclusion
Our historical perspective on the financial developments of vac-
cination programmes shows that while vaccination programmes
have become more expensive, they have a relatively low impact
on overall healthcare expenditure, and have been highly cost-
effective in reducing mortality burden. While recent vaccines are
progressively more expensive, over time, the costs of implemented
vaccinations tend to decline. It is important to understand the
financial evolution of vaccination programmes as it provides the
context for today’s decision-making.Funding
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